Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $221.5MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was incorporated in 2019 and is based in Aliso Viejo, California.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ra Capital Management, L.p. | Director | Feb 09 '26 | Buy | $16.00 | 3,690,000 | $59,040,000 | 5,966,439 | Feb 11 05:15 PM |
| Behbahani Ali | Director | Feb 09 '26 | Buy | $16.00 | 937,500 | $15,000,000 | 6,035,038 | Feb 11 04:30 PM |
| Florence Anthony A. Jr. | 10% Owner | Feb 09 '26 | Buy | $16.00 | 937,500 | $15,000,000 | 6,035,038 | Feb 11 04:30 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.